Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 4/20 | 0.47 |
| ▸ | HTR2C | P28335 | 4/20 | 0.47 |
| ▸ | HTR2B | P41595 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
| ▸ | G6PD | P11413 | 1/20 | 0.40 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.40 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15682035 | 0.84 | CA2 (0.47) | ALDH1A1MAPTRAB9AMAPK1NPSR1 | |
| SCHEMBL19756643 | 0.84 | HTR2A (0.46) | HTR2AHTR2CHTR2BALDH1A1MAPT | |
| SCHEMBL12957891 | 0.82 | HTR2A (0.41) | HTR2AHTR2CHTR2BALDH1A1MAPT | |
| SCHEMBL24724645 | 0.82 | MEP1B (0.44) | HTR2AHTR2CHTR2BALDH1A1MAPT | |
| SCHEMBL15594069 | 0.82 | HTR2A (0.45) | HTR2AHTR2CHTR2BALDH1A1MAPT | |
| SCHEMBL27192441 | 0.80 | HTR2A (0.41) | HTR2AHTR2CHTR2BALDH1A1MAPT | |
| SCHEMBL25237243 | 0.80 | HTR2A (0.41) | HTR2AHTR2CHTR2BALDH1A1MAPT | |
| SCHEMBL6736267 | 0.80 | HTR2A (0.44) | HTR2AHTR2CHTR2BALDH1A1MAPT | |
| SCHEMBL23723768 | 0.80 | ALDH1A1 (0.41) | HTR2AHTR2CHTR2BALDH1A1MAPT | |
| SCHEMBL15685342 | 0.80 | HTR2A (0.41) | HTR2AHTR2CHTR2BALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021113627-A1 | SUBSTITUTED TETRAHYDROFURANS AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-06-10 | — | — | WO | disclosed |
| US-20170369486-A1 | GEMINAL SUBSTITUTED QUINUCLIDINE AMIDE COMPOUNDS AS AGONISTS OF ALPHA-7 NICOTONIC ACETYLCHOLINE RECEPTORS | AXOVANT SCIENCES GMBH (CH) | 2017-12-28 | — | — | US | disclosed |
| EP-1138657-A1 | Process for generating electrophiles from anions by reaction with electrophilic fluorinating agent | AIR PRODUCTS AND CHEMICALS, INC. (US) | 2001-10-04 | — | — | EP | disclosed |
| US-6270843-B1 | REACTING A SALT COMPRISING ANIONIC FORM OF SUBSTITUENT WITH AN ELECTROPHILIC FLUORINATION AGENT TO PROVIDE AN ELECTROPHILE COMPRISING CATIONIC FORM OF SUBSTITUENT; ELECTROPHILICALLY SUBSTITUTING ELECTROPHILE ON SUBSTRATE | AIR PRODUCTS AND CHEMICALS, INC. | 2001-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170369486-A1 | GEMINAL SUBSTITUTED QUINUCLIDINE AMIDE COMPOUNDS AS AGONISTS OF ALPHA-7 NICOTONIC ACETYLCHOLINE RECEPTORS | CHRNA7, CHRNA6, CHRNA5 | HTR2A 1434/4885HTR2C 1138/4885HTR2B 1422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.